Application of n-3 Fatty to Patient of Jaundice

Huazhong University of Science and Technology

Status: Completed

Conditions: Surgical Procedure, Unspecified; Obstructive Jaundice

Treatments: Drug: control cohort; Drug: trail cohort

Study type: Observational

Funder types: Other

Identifiers

NCT03376945

Chenxp009

Details and patient eligibility

About

The safety and efficacy of ω-3 fatty acid in patients with obstructive jaundice is not known. This study provided evidences that ω-3 fatty acid-based parenteral nutrition improved postoperative recovery for patients with obstructive jaundice.

Full description

Lipid emulsion enriched in n-3 fatty acid (FA) has been reported to improve postoperative recovery for surgical patients with biliary tract disease, and to improve laboratory and clinical outcomes. The role of it for postoperative patients with jaundice is not clear yet. The object of this research was to evaluate the safety and efficacy of n-3 fatty acid-based parenteral nutrition (PN) for patients with jaundice following Surgical procedure.

This cohort study was a pragmatic, retrospective, single center, matched, clinical trial from May 2014 to June 2017.

Enrollment: 106 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• the diagnosis of obstructive jaundice must be clear (serum toal bilirubin >51.3umol/L & Imaging evidence), and the obstruction is located in the extrahepatic bile duct;
• Duration of Jaundice is less than 2 weeks;
• Nutritional support is needed
• Nutritional support was administrated during the perioperative period;
• Drainage treatment is effective.

Exclusion criteria

• Contraindication for surgical procedure, including Child-Pugh Classification C, severe hemorrhagic disorders, gastrointestinal hemorrhage, acute infectious disease, active phase of chronic hepatitis B & C, severe circulatory disease, renal failure pre -operation, and other unknown cause;
• Abandon treatment;
• Length of stay in hospital <5 day;
• Nutrition support <5 day;
• Conservative treatment;
• Incomplete data;
• Allergic reactions against PN.

Trial design

106 participants in 2 patient groups

trail cohort

Description:

n-3 FAs

Treatment:

Drug: trail cohort

control cohort

Description:

Structolipid

Treatment:

Drug: control cohort